樹状細胞がんワクチンの世界市場規模：製品タイプ別、エンドユーザー別、地域範囲別、予測

樹状細胞がんワクチンの市場規模と予測

樹状細胞がんワクチン市場規模は、2024年に24億1,000万米ドルと評価され、2026年から2032年にかけてCAGR 10.5%で成長し、2032年には51億8,000万米ドルに達すると予測されます。

• 樹状細胞は、がん細胞を含む異常な細胞を識別し排除する免疫系を助ける。科学者たちはワクチンを作るために、樹状細胞をがん細胞と一緒に研究室で培養します。私たちの免疫システムは、ワクチンによって悪性腫瘍と闘うよう促されます。
• 第II相研究では、樹状細胞免疫によって腫瘍に侵入するリンパ球の数が増加し、免疫反応が誘発され、一部の患者において全生存期間が改善する可能性が示されました。
• ワクチンの製造には、β細胞タンパク質と樹状細胞として知られる患者自身の免疫細胞が使用されます。このワクチン接種は、免疫系にβ細胞を攻撃するように指示することによって、β細胞が治癒し、血糖値を調節するのに十分なインスリンを産生するのを助けるかもしれないです。
• 転移性前立腺がん、腎細胞がん、神経膠腫、メラノーマなど複数の腫瘍が、樹状細胞がんワクチンの臨床試験の対象となっています。

樹状細胞がんワクチンの世界市場力学

世界の樹状細胞がんワクチン市場を形成している主な市場力学は以下の通り：

主な市場促進要因

• がん罹患率の増加：毎年数百万件の新たな症例が報告されており、がんは世界規模で深刻な公衆衛生上の問題です。樹状細胞がんワクチンのような新規かつ効率的な治療法の創出は、がん有病率の上昇に大きく後押しされています。
• 免疫療法の利用拡大：免疫療法は、がん細胞と闘うために免疫系を刺激するがん治療です。臨床試験で可能性が示されている免疫療法のひとつに、樹状細胞ワクチンの使用があります。樹状細胞がんワクチンの需要は、免疫療法が普及するにつれて増加すると予測されます。
• 技術の進歩：技術の進歩により、より正確で強力な樹状細胞がんワクチンが可能になりました。例えば、科学者は樹状細胞を分離・刺激するだけでなく、樹状細胞ワクチンを体内に投与するための新しいアプローチを開発しています。
• 研究開発費の増加：製薬会社や政府機関は、樹状細胞がんに対するワクチンの研究や開発に多額の投資を行っています。今後数年間は、この投資によって新しく改良された予防接種が開発されることが期待されます。

主な課題

• 製造の複雑さ：樹状細胞がんワクチンの製造手順は、患者自身の免疫細胞を除去し、がんを標的とするように実験室で改変し、その後免疫細胞を患者に再導入します。ワクチン製造は複雑なため、コストと時間がかかります。
• 限られた有効性：いくつかの調査では有望な結果が得られているが、デンドライト細胞がんワクチン接種は様々ながん種に対して信頼性の低い治療法であることが証明されつつあります。これらのワクチン接種の有効性を高めるため、研究者らは製造プロセスの改善を試みています。
• 技術の進歩樹状細胞がんワクチン市場は、技術の進歩によって活性化しています。個別化されたワクチン接種と、この治療法の恩恵を最も受けそうな患者の特定は、人工知能（AI）によって促進されています。さらに、ゲノミクスによって腫瘍の最適な標的を特定することが可能になりつつあり、その結果、より効果の高いワクチンが生み出されることになります。AIはまた、複雑な製造プロセスを簡素化し、コストを下げ、利用しやすくする可能性もあります。技術開発の融合により、強力でカスタマイズされた樹状細胞がんワクチン開発の扉が開かれつつあります。

主要動向

• 抗原探索：ゲノム解読は、腫瘍特異的抗原、すなわち免疫学的反応を誘導する化学物質の発見に役立ちます。これらの抗原が免疫系を刺激する能力をAIが分析・予測することで、より専門的なワクチン開発が可能になります。
• 腫瘍の不均一性：同じがん患者でも腫瘍の遺伝子構成が異なるため、樹状細胞がんワクチンの需要が高まっています。
• 専門知識の組み合わせ：新興企業は最先端の技術や特徴的な抗原ターゲットを持つことが多いが、既存企業は製造、規制手続き、臨床試験に関する知識を提供します。それぞれのスキルを組み合わせることで、個々の限界を克服し、ワクチン開発を加速することができます。

目次

第1章 樹状細胞がんワクチンの世界市場導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 樹状細胞がんワクチンの世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 樹状細胞がんワクチンの世界市場：製品タイプ

• 概要
• Sipuleucel-T
• CreaVax

第6章 樹状細胞がんワクチンの世界市場：エンドユーザー別

• 概要
• 小児
• 成人

第7章 樹状細胞がんワクチンの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 樹状細胞がんワクチンの世界市場競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第9章 企業プロファイル

• GlaxoSmithKline plc
• 3M Company
• Activartis
• Batavia Bioservices
• Argos Therapeutics
• Sanpower Corporation
• Elios Therapeutics
• DanDrit Biotech
• DCPrime
• ImmunoCellular Therapeutics

第10章 主な発展

• 製品上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第11章 付録

• 関連調査

Dendritic Cell Cancer Vaccine Market Size And Forecast

Dendritic Cell Cancer Vaccine Market size was valued at USD 2.41 Billion in 2024 and is projected to reach USD 5.18 Billion by 2032, growing at a CAGR of 10.5% from 2026-2032.

• Dendritic cells aid the immune system in identifying and eliminating aberrant cells, including cancerous cells. Scientists cultivate dendritic cells alongside cancer cells in the lab in order to create the vaccine. Our immune system is then prompted to combat the malignancy by the vaccine.
• In phase II studies, it was demonstrated that dendritic cell immunization might boost the number of lymphocytes invading tumors, trigger an immune response, and improve overall survival for a subset of patients.
• A beta-cell protein and the patient's own immune cells, known as dendritic cells, are used to make the vaccine. The vaccination may help the beta-cells heal and produce adequate insulin to regulate blood sugar levels by instructing the immune system to attack on beta-cells.
• Multiple tumors, including metastatic prostate cancer, renal cell carcinoma, glioma, and melanoma, have been subjected to a clinical trial of the Dendritic Cell Cancer Vaccination.

Global Dendritic Cell Cancer Vaccine Market Dynamics

The key market dynamics that are shaping the global Dendritic Cell Cancer Vaccine Market include:

Key Market Drivers:

• Growing Cancer Prevalence: With millions of new cases reported each year, cancer is a serious public health concern on a global scale. The creation of novel and efficient therapies, such as dendritic cell cancer vaccines, is largely fueled by the rising prevalence of cancer.
• Expanding Use of Immunotherapy: Immunotherapy is a cancer treatment that stimulates the immune system to combat cancer cells. One type of immunotherapy that has shown potential in clinical trials is the use of dendritic cell vaccines. Dendritic cell cancer vaccine demand is predicted to increase as immunotherapy gains traction.
• Technology Advancements: More precise and potent dendritic cell cancer vaccines are now possible because due to technological advancements. For instance, scientists are creating novel approaches for delivering these vaccinations to the body as well as for isolating and stimulating dendritic cells.
• Rising R&D Expenditure: Drug companies and government agencies are making significant investments in the study and creation of vaccines against dendritic cell cancer. In the upcoming years, it is anticipated that this investment will result in the development of new and improved vaccinations.

Key Challenges:

• Complexity of Manufacturing: The procedure of creating dendrite cell cancer vaccines is removing a patient's own immune cells, modifying them in a laboratory to target the cancer, and then reintroducing the immune cells to the patient. The production of the vaccinations is costly and time-consuming due to their complication.
• Limited Efficacy: Although some research has yielded encouraging results, dendrite cell cancer vaccinations is proving an unreliable treatment for various cancer types. To increase the effectiveness of these vaccinations, researchers are trying to improve their manufacturing process.
• Technological Advancements: Dendritic Cell Cancer Vaccine Market is boosting thanks to the technological advancement. Personalized vaccinations and the identification of patients most likely to benefit from this therapy are being facilitated by artificial intelligence (AI). Furthermore, genomics is making it possible to identify the best tumor targets, which will result in vaccines that work better. AI is also simplifying the intricate manufacturing process, which could lower costs and improve accessibility. The convergence of technological developments is opening doors for the development of potent and customized dendritic cell cancer vaccines.

Key Trends:

• Antigen Discovery: Genomic sequencing aids in the discovery of tumor-specific antigens, or immunological response-inducing chemicals. The development of more specialized vaccinations will result from AI's analysis and prediction of these antigens' capacity to stimulate the immune system.
• Heterogeneity of Tumors: The difference in the genetic makeup of tumors even among patients with the same form of cancer is increasing the demand for dendritic cell cancer vaccine.
• Combination of Expertise: While new firms frequently have cutting-edge technologies or distinctive antigen targets, established players provide knowledge in manufacturing, regulatory procedures, and clinical trials. They can overcome individual limits and accelerate the development of vaccines by combining their skills.

Global Dendritic Cell Cancer Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the global Dendritic Cell Cancer Vaccine Market:

North America:

• According to Verified Market Research analyst, North America is expected to hold a major share in the global Dendritic Cell Cancer Vaccine Market. North America has dominated the Dendritic Cell Cancer Vaccine Market mostly due to large-scale research studies funded by pharmaceutical companies and university research institutes, as well as an extraordinary surge in the prevalence of cancer cases.
• North American region spend a lot on healthcare, more money may be allocated to the study and creation of cutting-edge cancer treatments, such as dendrite cell cancer vaccinations.
• North America has the biggest market share due to increased awareness of cancer treatment and the availability of well-developed healthcare infrastructure and research facilities.
• In North America, there is a growing awareness of cancer and accessible treatment choices, which could lead to increasing patient interest in tailored therapies like DC vaccines.

Asia Pacific:

• Several countries in Asia-Pacific are actively sponsoring cancer immunotherapy research and development, including DC vaccines. This involves sponsoring programs and reducing regulatory procedures. Countries are developing reimbursement schemes for approved DC vaccines, making them more available to patients.
• The evolving healthcare system present encouraging prospects for market growth. Even though the market is still developing in comparison to North America and Europe, a number of domestic and foreign companies are actively engaged in research partnerships and clinical trials. This strong activity suggests that the Asia Pacific area has enormous potential to influence the direction of cancer treatment using dendritic cells.
• There is a growing need for new treatment alternatives due to the increased incidence of cancer cases in nations like China and India. A climate that is conducive to the uptake of dendritic cell vaccines is being created by rising public knowledge of immunotherapy and government backing for it.

Global Dendritic Cell Cancer Vaccine Market: Segmentation Analysis

The Global Dendritic Cell Cancer Vaccine Market is segmented on the basis of Product Type, End-User, and Geography.

Dendritic Cell Cancer Vaccine Market, By Product Type

• Sipuleucel-T
• CreaVax

Based on Product Type, the market is bifurcated into Sipuleucel-T and CreaVax. Sipuleucel-T has the greatest share of the market among the others. The treatment of metastatic prostate cancer in males with sipuleucel-T is clinically authorized. with growing in acceptance. Sipuleucel-T, formerly known as Provenge, is now the market leader for dendritic cell cancer vaccines. This is due to its unique status as the first cancer immunotherapy to receive FDA approval.

• Sipuleucel-T is a targeted treatment for men with metastatic castration-resistant prostate cancer who are asymptomatic or very symptomatic. Even though there are currently other dendritic cell vaccines being developed, Sipuleucel-T's established presence and demonstrated efficacy are probably going to help it maintain its market share going forward.

Dendritic Cell Cancer Vaccine Market, By End-User

• Pediatric
• Adults

Based on End-User, the market is bifurcated into Pediatric and Adults. In the market for cancer vaccines against dendritic cell carcinoma, the adult category is dominant. Numerous factors contribute to this supremacy. First off, adult cancer incidence rates are often higher than those in youngsters. Second, adult malignancies such as lung, breast, and prostate cancers are the focus of a sizable fraction of current clinical trials for dendritic cell vaccines.

• The purpose of these trials is to assess the novel medicines' safety and effectiveness in adult patients. Furthermore, well-known competitors in the market, such as the company that created Sipuleucel-T (Provenge), focus mostly on adult patients. Although there is ongoing research into pediatric dendritic cell vaccines, the adult segment currently holds a dominant position in the market due to its established therapeutic choices and state of research.

Key Players

The "Global Dendritic Cell Cancer Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are GlaxoSmithKline plc, 3M Company, Activartis, Batavia Bioservices, Argos Therapeutics, Sanpower Corporation, Elios Therapeutics, DanDrit Biotech, DCPrime, and ImmunoCellular Therapeutics.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Dendritic Cell Cancer Vaccine Market Recent Developments
• In September 2021, the development of immunotherapeutic techniques has allowed for the improvement of standard therapies' efficacy in the treatment of oncological disorders. Following the introduction of dendritic cell-based individualized therapeutic vaccines into clinical practice there was no significant advancement. The scope of use for dendritic cell (DC) vaccines has been expanded, and patient indicators for cancer have improved to a clearer understanding of dendritic cell biology and the adoption of novel techniques and agents for antigenic work. Furthermore, encouraging projections of DC vaccines application in broader clinical practice can be used due to their low toxicity in clinical trials.
• In June 2021, ASPAGNIITM was being used in dendritic cell (DC) based immunotherapy in cervical, ovarian cancer and will also be used in breast cancer. The process begins by extracting monocytes of white blood cell from the patient's blood. These monocytes are then transformed into dendritic cells which act as immune system messengers. The dendritic cells are equipped with a specific protein called ASPAGNIITM. This protein helps them recognize and target cancer cells expressing SPAG9. Finally, after being primed the dendritic cells are reintroduced into the body and there, they guide T cells to identify and destroy the cancer cells.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL DENDRITIC CELL CANCER VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL DENDRITIC CELL CANCER VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL DENDRITIC CELL CANCER VACCINE MARKET, PRODUCT TYPE

• 5.1 Overview
• 5.2 Sipuleucel-T
• 5.3 CreaVax

6 GLOBAL DENDRITIC CELL CANCER VACCINE MARKET, END-USER

• 6.1 Overview
• 6.2 Pediatric
• 6.3 Adults

7 GLOBAL DENDRITIC CELL CANCER VACCINE MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East & Africa

8 GLOBAL DENDRITIC CELL CANCER VACCINE MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 GlaxoSmithKline plc
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 3M Company
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Activartis
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Batavia Bioservices
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Argos Therapeutics
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Sanpower Corporation
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Elios Therapeutics
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 DanDrit Biotech
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 DCPrime
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 ImmunoCellular Therapeutics
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research